Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. A subsequent 8-week course may be considered for patients who have not healed.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily.
* **Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** Starting dose is 40 mg orally or intravenously twice daily. Doses may be increased to up to 240 mg intravenously daily or 120 mg orally twice daily. Doses greater than 40 mg twice daily should be administered via continuous intravenous infusion.
* **Maximum dose:** Generally 40 mg once or twice daily orally/IV, but higher doses up to 240 mg IV daily are used for hypersecretory conditions under close monitoring.
## Pediatric Dosing
* **Erosive esophagitis (age 5 to 16 years):** 40 mg orally once daily for up to 4 weeks.
* **GERD symptoms (age 5 to 16 years):** 20 mg orally once daily for up to 4 weeks.
* **Note:** Dosing for pediatric patients is often based on weight and clinical response. Consult specific pediatric guidelines or institutional protocols.
## Dose Adjustments
* **Hepatic impairment:** Reduce daily dose by one-half (e.g., 40 mg once daily or every other day). Maximum dose is 40 mg daily.
* **Renal impairment:** No dose adjustment is generally recommended.
## Contraindications
* Known hypersensitivity to pantoprazole, any other component of the formulation, or any other substituted benzimidazole.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:**
* *Clostridium difficile*-associated diarrhea
* Fracture of the hip, wrist, or spine (with long-term use)
* Hypomagnesemia (with long-term use, especially if co-administered with digoxin or other drugs that cause hypomagnesemia)
* Vitamin B12 deficiency (with long-term use)
* Systemic lupus erythematosus (SLE)
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** PPIs can decrease absorption of drugs such as ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12.
* **Methotrexate:** Pantoprazole may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel (reduced antiplatelet effect), citalopram, and diazepam.
* **Warfarin:** May increase INR and prothrombin time in patients receiving warfarin. Monitor INR closely.
* **Didanosine:** Concomitant use may increase didanosine levels.
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider monitoring magnesium levels, especially with prolonged therapy (>3 months) or concomitant use of other medications that can lower magnesium (e.g., diuretics).
* Monitor for bone fracture risk with long-term use.
* Assess for symptoms of vitamin B12 deficiency with prolonged therapy.
## Clinical Pearls
* Pantoprazole is generally considered less likely to interact with clopidogrel compared to omeprazole or esomeprazole due to weaker CYP2C19 inhibition. However, caution is still advised.
* IV administration is primarily for patients unable to take oral medication. When switching from IV to oral, consider the total daily dose.
* For long-term use, consider the lowest effective dose and shortest duration necessary to treat the condition.
* Consider risk factors for osteoporosis and bone fractures in patients on long-term PPI therapy.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines for complete and up-to-date information.
